Data presented by Celltrion Healthcare at the European Crohn’s and Colitis Organization outlined the benefits of subcutaneous (SC) infliximab.
New data from Celltrion Healthcare show the subcutaneous (SC) form of infliximab, Remsima (CT-P13), yielded superior benefits in patients with inflammatory bowel disease (IBD) compared with intravenous (IV) dosing.
Findings presented at the European Crohn’s and Colitis Organization (ECCO) virtual congress 2022 also showed maintenance therapy with Remsima SC resulted in stable drug levels across a 14-day treatment cycle in a remitted patient with Crohn disease (CD), meaning drug monitoring could be performed at any time between the 2 injections, increasing patient convenience.
Celltrion’s infliximab was the first monoclonal antibody biosimilar to receive approval from the European Commission and is currently indicated for 8 autoimmune diseases, including IBD and rheumatoid arthritis.
Whereas infliximab IV must be given as an infusion over the course of 2 hours while patients are monitored for 1 to 2 hours afterward, the SC dose can be administered via a pre-filled pen, pre-filled syringe, or pre-filled syringe with needle safeguard. In the European Union, a 120 mg fixed dose of SC infliximab has been granted marketing authorization for adults regardless of body weight.
In the REMSWITCH study, 130 patients in remission (73% with CD and 26.9% with ulcerative colitis [UC]) were switched from 3 different IV dose regimens to SC infliximab at 120mg every 2 weeks.
After switching, analyses showed average Infliximab trough levels were significantly higher (9.8 [6.4] µg/ml vs 14.4 [5.7] µg/ml; P<.0001), with levels increased among patients who underwent 5mg/kg/8weeks or 10mg/kg/8weeks IV regimen. Levels remained stable in those who were treated with 10mg/kg/6weeks or 10mg/kg/4weeks of IV Remsima.
Data also revealed:
Patients reported greater acceptability of the SC injection compared with IV infusions.
Additional research was presented from the RDTM study evaluating intra-individual variations of the drug levels at different time points throughout 2 consecutive cycles of maintenance therapy.
“This is the first real-world study analyzing serum levels of infliximab at different time-points between 2 SC injections of infliximab and during 2 cycles at steady state during maintenance regimen in remitted CD patient,” said Xavier Roblin, MD, of the department of gastroenterology at the University Hospital of Saint-Etienne in France. “Our results clearly demonstrated stable levels of infliximab all over this period.”
Approximately 5 million individuals worldwide suffer from IBD.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD
June 29th 2024Two phase 3 trials in patients with inflammatory bowel disease (IBD) found higher clinical remission rates in those treated with the subcutaneous formulation of infliximab biosimilar CT-P13 compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.